Skip to main content

Covid-19 vaccine to be delivered to all Russian regions on 14 Sept: Official

By Unknown

The first batch of Russia's Covid-19 vaccine 'Sputnik V' is likely to be delivered to all regions of the country by Monday, 14 September, Russian Health Minister Mikhail Murashko told reporters, according to news agency TASS.

"The first batches of the vaccine for testing the supply chain have already been shipped, we are now checking the delivery system so that the staff gets to know it. The first small batches have already been shipped to all regions, the Leningrad region will also receive [the vaccine] among the first ones. In fact, the first samples of the vaccine will be delivered by Monday," Murashko said.

The development comes after a week of Russia releasing the first batch of the Sputnik V vaccine into civil circulation, the Russian Health Ministry informed.

Sputnik V Covid vaccine, which is developed by Gamaleya Research Institute of Epidemiology and Microbiology under the Russian Health Ministry, may be granted permission to release a batch of its vaccine for civilian use, the institute’s deputy director for research, associate member of the Russian Academy of Sciences, Denis Logunov said earlier, according to a report.

A Phase III trial is a large-scale one involving thousands of people - in Russia, 40,000 - over a longer stretch of time.

RDIF said on Friday that more than one billion people would receive its COVID-19 vaccine "Sputnik-V" in 2020-21, the Interfax news agency reported.

Meanwhile, Russian children have returned to schools after attending classes online since the coronavirus pandemic swept the country in late March.

Moreover, country's sovereign wealth fund CEO on Saturday said he's 'delighted' that AstraZeneca has resumed trials of its Covid-19 vaccines but said the suspension of trials "clearly showed fallacy of their approach".

"Delighted that AstraZeneca has resumed trials. Suspension of trials clearly showed fallacy of the approach, when entire countries exclusively rely on novel and untested platforms when choosing a vaccine for widespread use, including the use of a monkey adenovirus vector or mRNA technology," said Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF).

AstraZeneca has resumed British clinical trials of its Covid-19 vaccine, one of the most advanced in development, after receiving the green light from safety watchdogs, the company said on Saturday

On August 11, Russia became the first country to license a Covid-19 vaccine, calling it "Sputnik V" in homage to the world's first satellite, launched by the Soviet Union. But western experts have warned against its use until all internationally approved testing and regulatory steps have been taken. The vaccine is undergoing Phase 3 trials.

The vaccine produced an antibody response in all participants in early-stage trials, according to results published by The Lancet medical journal earlier that were hailed by Moscow as an answer to its critics.

The results of the two trials, conducted in June-July this year and involving 76 participants, showed 100% of participants developing antibodies to the new coronavirus and no serious side effects, The Lancet said.

However, a group of international scientists questioned results from the Lancet medical journal, saying some of the findings appeared improbable, reported Bloomberg.

The researchers flagged concerns over seemingly identical levels of antibodies in a number of study participants who were inoculated with the experimental vaccine. This and other patterns in the data present “several different points of concern," according to an open letter written by Temple University professor Enrico Bucci and signed by more than a dozen other scientists.

Amid the reports of the potential vaccine, Russia registered 5,449 COVID-19 cases in the past 24 hours, which brings the cumulative total to 1,062,811, the country's coronavirus response centre said on Sunday.

"Over the past 24 hours, Russia has confirmed 5,449 COVID-19 cases in 84 regions, of which 1,238 (23.5 per cent) have been detected actively, with people showing no clinical symptoms," the response centre said in a statement.


Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more

Context & pre-existing barriers to education for girls and women

By Unknown
Education is a right for all children and an educated population is essential for building a self-reliant, peaceful, equal, and inclusive Afghan society. Afghanistan’s education system has been severely impacted by decades of conflict, widespread poverty and humanitarian crisis.  Today, funding remains insufficient, as only 3% of Afghanistan’s Gross Domestic Product is allocated to education. International standards state that the government should spend at least 4 to 6% of GDP on education.  The Incheon Declaration and Framework for Action for the implementation of Sustainable Development Goal 4 recognizes that to “ensure inclusive and equitable quality education and promote lifelong learning opportunities for all”, least developed countries need to dedicate at least or more than 4 to 6%.  Afghanistan budgets far less than this, and even with this small percentage of funding the country’s education budget continues to be underspent every year.Afghanistan has one of the y...
Post a Comment
Read more